Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Although left ventricular (LV) diastolic dysfunction is often associated with hypertension, little is known regarding its underlying pathophysiological mechanism. Here, we show that the actin cytoskeletal regulator, Rho-associated coiled-coil containing kinase-2 (ROCK2), is a critical mediator of LV diastolic dysfunction. In response to angiotensin II (Ang II), mutant mice with fibroblast-specific deletion of ROCK2 (ROCK2Postn-/-) developed less LV wall thickness and fibrosis, along with improved isovolumetric relaxation. This corresponded with decreased connective tissue growth factor (CTGF) and fibroblast growth factor-2 (FGF2) expression in the hearts of ROCK2Postn-/- mice. Indeed, knockdown of ROCK2 in cardiac fibroblasts leads to decreased expression of CTGF and secretion of FGF2, and cardiomyocytes incubated with conditioned media from ROCK2-knockdown cardiac fibroblasts exhibited less hypertrophic response. In contrast, mutant mice with elevated fibroblast ROCK activity exhibited enhanced Ang II-stimulated cardiac hypertrophy and fibrosis. Clinically, higher leukocyte ROCK2 activity was observed in patients with diastolic dysfunction compared with age- and sex-matched controls, and correlated with higher grades of diastolic dysfunction by echocardiography. These findings indicate that fibroblast ROCK2 is necessary to cause cardiac hypertrophy and fibrosis through the induction CTGF and FGF2, and they suggest that targeting ROCK2 may have therapeutic benefits in patients with LV diastolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
The pathophysiology of heart failure with preserved ejection fraction
Borlaug, B. A. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.83 · Cited by 726 · cited 2×
“Whereas effective medical and surgical treatments for HF with reduced LV function are available, such as angiotensin (Ang) converting enzyme inhibitors (6), cardiac transplantation (7), and LV assist devices (8), the treatment for LV diastolic dysfunction is more limited (9).”
BackgroundWestermann, D., Lindner, D., Kasner, M., Zietsch, C., Savvatis, K., Escher, F., von Schlippenbach, J., Skurk, C., Steendijk, P., Riad, A., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.931451 · Cited by 644 · cited 1×
“One of the main cellular features of diastolic dysfunction is the activation of fibroblasts, which in turn increase type I collagen production and reduce matrix metalloproteinase–1 activity, thereby increasing diastolic stiffness through collagen deposition in the extracellular matrix (29).”
BackgroundWang, W., Wang, Y., Long, J., Wang, J., Haudek, S. B., Overbeek, P., Chang, B. H. J., Schumacker, P. T., & Danesh, F. R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.009 · Cited by 476 · cited 1×
“The caROCK construct containing the amino-terminal kinase domain of human ROCK1 under the control of ubiquitin-C (UbiC) promoter, which was deactivated by loxP-Stop-loxP cassettes, was inserted into the murine ubiquitous Rosa-26 locus (47).”
MethodKnipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Self-citation
Cited by
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Fibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
Zanin-Zhorov, A., & Blazar, B. R. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108823 · Cited by 74
Metadata
- Authors
- Shimizu, T., Narang, N., Chen, P., Yu, B., Knapp, M., Janardanan, J., Blair, J., & Liao, J. K.
- Venue
- JCI Insight
- Published
- 2017-07-06
- Volume
- 2
- Issue
- 13
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2732060764
- Cited by
- 75
- References
- 7
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. https://app.cochat.ai/papers/10.1172/jci.insight.93187
- The paper
- Shimizu, T., Narang, N., Chen, P., Yu, B., Knapp, M., Janardanan, J., Blair, J., & Liao, J. K. (2017). Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight. https://doi.org/10.1172/jci.insight.93187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.